Story perspectives

Breakthrough Gene Therapy Shows Promise for Neurological Disorders

9/18/2025

Summary

Story summary

UCSF researchers used CRISPR-based gene activation to restore SCN2A function in preclinical models, suggesting a potential treatment for neurological disorders.
Increased SCN2A expression compensates for mutations associated with autism and epilepsy.
SCN2A-related epilepsy presents a range of phenotypes, highlighting its importance in neuronal excitability.
Ongoing studies investigate gene therapy for genetic neurodevelopmental disorders like Angelman and Dravet syndromes.
These findings enhance understanding of genetic disorders and support targeted gene therapy development.

1 of 1

Story summary

UCSF researchers used CRISPR-based gene activation to restore SCN2A function in preclinical models, suggesting a potential treatment for neurological disorders.
Increased SCN2A expression compensates for mutations associated with autism and epilepsy.
SCN2A-related epilepsy presents a range of phenotypes, highlighting its importance in neuronal excitability.
Ongoing studies investigate gene therapy for genetic neurodevelopmental disorders like Angelman and Dravet syndromes.
These findings enhance understanding of genetic disorders and support targeted gene therapy development.